DEF: Health In Tech Seeks Shareholder Approval for Growth Initiatives

Health In Tech, Inc. has issued a proxy statement detailing proposals for its 2026 Annual Meeting, including a significant increase in authorized shares, approval of a standby equity purchase agreement, and amendments to its equity incentive plan.

Summary

• Health In Tech, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on November 10, 2026.
• Key proposals include electing five directors, increasing authorized shares from 220 million to 720 million, approving a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. for up to $20 million, and amending the 2024 Equity Incentive Plan to increase share availability.
• The company also seeks to ratify the appointment of Malone Bailey, LLP as its independent auditors for 2026.
• The meeting will be conducted virtually, with stockholders needing a control number to participate and vote.
• The record date for determining eligible stockholders is September 18, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, as it outlines necessary steps for future growth and operational needs, though it involves potential dilution and increased authorized shares.

Positives

• The company is proactively seeking shareholder approval for measures aimed at facilitating future financing and operational flexibility.
• The proposed increase in authorized shares and the SEPA provide potential access to significant capital ($20 million) to fund operations, expansion, and development.
• The amendment to the Equity Incentive Plan aims to attract and retain talent, crucial for growth.
• The election of experienced directors and ratification of auditors suggest a commitment to good governance and financial oversight.

Negatives

• The proposed increase in authorized shares from 220 million to 720 million, and the potential issuance of up to $20 million in Class A Common Stock through the SEPA, will likely result in substantial dilution for existing shareholders.
• The SEPA allows for the issuance of shares at prices potentially below market value (97% of VWAP), further exacerbating dilution.
• The company is currently not in compliance with Nasdaq's majority independent board requirement and three-member Audit Committee requirement, though it has a cure period until February 6, 2027.

Risks

• Substantial dilution to existing shareholders due to the proposed increase in authorized shares and the SEPA financing.
• Potential for market price decline of Class A Common Stock due to the perception or actual issuance of a large number of shares under the SEPA.
• The company's current non-compliance with Nasdaq's majority independent board and Audit Committee size requirements poses a risk if not rectified within the cure period.
• The SEPA includes restrictions on other financings and related party payments until outstanding convertible notes are repaid.

Future Outlook

The company is seeking to increase its authorized share capital and secure a standby equity purchase agreement to provide flexibility for future financings, acquisitions, stock dividends/splits, and employee benefit plans. The proposed amendment to the equity incentive plan aims to support ongoing talent acquisition and retention.

Management Comments

• The Board of Directors believes it is desirable for the Company to have a sufficient number of shares of Class A Common Stock available for the satisfaction of its existing obligations to issue shares of Class A Common Stock and possible future financings or acquisition transactions, stock dividends or splits, stock issuances pursuant to employee benefit plans and other proper corporate purposes.
• The Board of Directors believes that approval of the Share Authorization Proposal is crucial predominantly to ensure that the Company has sufficient authorized shares to meet its existing obligations to issue shares of Common Stock as and if they become due, and to secure needed financing without incurring the delay and expense of holding additional stockholders meetings.
• The Board of Directors has determined that the SEPA and our ability to issue the Class A Common Stock thereunder in excess of the Exchange Cap are in the best interests of the Company and its stockholders because it provides us a mechanism for raising additional capital.
• We believe the proceeds that we expect to receive pursuant to the SEPA, and the proceeds we did and will receive from the issuance of the Convertible Notes will allow us to fund our business operations.
• We expect that the SEPA will provide us with future flexibility to enhance our liquidity in an opportunistic and efficient manner, and only when we deem it to be necessary.
• We remain focused on creating long-term value for our stockholders, and the SEPA will allow us to be strategic in how we access and deploy capital to continue normal business operations.

Industry Context

StockSavvy.ai notes that increasing authorized shares and securing standby equity facilities are common strategies for growth-stage companies in the tech and healthcare sectors, particularly those aiming for significant expansion or facing capital-intensive development cycles. This approach allows for agility in fundraising but requires careful management to mitigate dilution.

Comparison to Industry Standards

• The proposed increase in authorized shares to 720 million represents a significant expansion from 220 million, a common practice for companies anticipating substantial future capital needs or stock-based compensation requirements.
• The SEPA with YA II PN, Ltd. is a financing mechanism often utilized by companies needing flexible access to capital, though the terms (discounted pricing, conversion features) are critical for comparison.
• The amendment to the Equity Incentive Plan to increase share pool size is standard practice for companies looking to attract and retain talent in competitive industries.
• Nasdaq listing rules regarding shareholder approval for significant share issuances (20% threshold) are a standard regulatory hurdle for companies listed on major exchanges.

Corporate Governance

Related Party Transactions

• There were no related party transactions during the years ended December 31, 2025, and 2024. No related party balances existed as of December 31, 2025, and 2024.

Stakeholder Impact

• Shareholders: Potential for significant dilution of ownership percentage and earnings per share due to proposed share increase and SEPA financing. Also, potential for increased capital to fund growth, which could lead to future value creation.
• Employees: The amendment to the Equity Incentive Plan aims to attract, retain, and incentivize employees, potentially leading to better performance and retention.
• Management: The SEPA includes a restriction on repaying related party debt until outstanding convertible notes are repaid, which could impact management's flexibility.
• Creditors: The SEPA also restricts the company from repaying certain other debts until the convertible notes are repaid, which could affect other creditors.

Next Steps

• Stockholders to vote on the five proposals at the 2026 Annual Meeting of Stockholders on November 10, 2026.
• If Proposal Two is approved, the company plans to file an amendment to its Articles of Incorporation promptly after the meeting.
• If Proposal Three is approved, the company can proceed with issuing shares under the SEPA in excess of the 19.99% threshold, subject to Nasdaq rules.
• If Proposal Four is approved, the 2024 Equity Incentive Plan will be amended to increase the share pool.
• The company intends to regain compliance with Nasdaq's majority independent board and Audit Committee size requirements by appointing new board members before February 6, 2027.

Key Dates

Recommendation

The filing presents a mixed outlook. While the proposed capital raise and equity plan amendments are positive for future growth, the significant potential for dilution from increasing authorized shares and the SEPA financing, coupled with current Nasdaq non-compliance, warrants a cautious approach. A 'hold' recommendation reflects the balance between potential upside from growth initiatives and the risks associated with dilution and governance issues.

Keywords

Proxy Statement, Annual Meeting, Shareholder Approval, Authorized Shares, Equity Incentive Plan, Standby Equity Purchase Agreement, Capital Raise, Director Election